ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the European Commission has ...

Learn more about the newly approved wearable treatment that disrupts pancreatic cancer tumor growth while letting patients continue daily life at home.

WASHINGTON (DC News Now) — September is Prostate Cancer Awareness Month, and according to the National Cancer Institute (NCI), approximately one in eight men will be diagnosed with prostate cancer in ...

Credit: Johnson & Johnson. Inlexzo is supplied as a single-dose intravesical system containing 225mg of gemcitabine plus a sterile urinary catheter and stylet. Inlexzo is an intravesical gemcitabine ...

SAN FRANCISCO, May 22, 2025 /PRNewswire/ -- OncoSwab, a biotechnology company focused on early detection of cancer through non-invasive molecular testing, today announced it has entered into a ...

Explore the OC-PAM AI tool that revolutionizes cancer research with non-invasive imaging of organoids and spheroids.

Devices shown at AI Impact Summit can be deployed across hospitals and resource-scarce settings to improve accuracy and accessibility.

The dual-modal technique combining OCT and Raman spectroscopy achieved 96.9% accuracy in differentiating melanoma from benign lesions. Early melanoma diagnosis is critical, with a 99% 5-year survival ...

Bladder cancer frequently announces itself through symptoms that patients dismiss as minor urinary issues, and that delay ...

Inlexzo is an intravesical gemcitabine releasing system that is inserted directly into the bladder through a urinary catheter. The Food and Drug Administration (FDA) has approved Inlexzo ™ ...